==== Front Transl Psychiatry Transl Psychiatry Translational Psychiatry 2158-3188 Nature Publishing Group UK London 2532 10.1038/s41398-023-02532-0 Article Exploratory genome-wide analyses of cortical inhibition, facilitation, and plasticity in late-life depression Wathra Rafae A. 12 http://orcid.org/0000-0003-1594-666X Men Xiaoyu 3 Elsheikh Samar S. M. 3 Marshe Victoria S. 3 http://orcid.org/0000-0002-8324-2560 Rajji Tarek K. 1234 http://orcid.org/0000-0003-0192-1453 Lissemore Jennifer I. 5 http://orcid.org/0000-0002-0303-6450 Mulsant Benoit H. 234 Karp Jordan F. 6 Reynolds Charles F. III 7 Lenze Eric J. 8 Daskalakis Zafiris J. 9 http://orcid.org/0000-0003-4978-4400 Müller Daniel J. 23 http://orcid.org/0000-0002-8422-5818 Blumberger Daniel M. daniel.blumberger@camh.ca 123 1 grid.155956.b 0000 0000 8793 5925 Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario M6J 1H4 Canada 2 grid.17063.33 0000 0001 2157 2938 Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario M5T 1R8 Canada 3 grid.155956.b 0000 0000 8793 5925 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8 Canada 4 grid.17063.33 0000 0001 2157 2938 Toronto Dementia Research Alliance, University of Toronto, Toronto, Ontario Canada 5 grid.240952.8 0000000087342732 Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA USA 6 grid.134563.6 0000 0001 2168 186X Department of Psychiatry, University of Arizona College of Medicine, Tucson, AZ USA 7 grid.21925.3d 0000 0004 1936 9000 Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA USA 8 grid.4367.6 0000 0001 2355 7002 Department of Psychiatry, Washington University School of Medicine, St Louis, MO USA 9 grid.266100.3 0000 0001 2107 4242 Department of Psychiatry, University of California San Diego, San Diego, CA USA 30 6 2023 30 6 2023 2023 13 2345 1 2023 16 6 2023 20 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Late-life depression (LLD) is a heterogenous mood disorder influenced by genetic factors. Cortical physiological processes such as cortical inhibition, facilitation, and plasticity may be markers of illness that are more strongly associated with genetic factors than the clinical phenotype. Thus, exploring the relationship between genetic factors and these physiological processes may help to characterize the biological mechanisms underlying LLD and improve diagnosis and treatment selection. Transcranial magnetic stimulation (TMS) combined with electromyography was used to measure short interval intracortical inhibition (SICI), cortical silent period (CSP), intracortical facilitation (ICF), and paired associative stimulation (PAS) in 79 participants with LLD. We used exploratory genome-wide association and gene-based analyses to assess for genetic correlations of these TMS measures. MARK4 (which encodes microtubule affinity-regulating kinase 4) and PPP1R37 (which encodes protein phosphatase 1 regulatory subunit 37) showed genome-wide significant association with SICI. EGFLAM (which encodes EGF-like fibronectin type III and laminin G domain) showed genome-wide significant association with CSP. No genes met genome-wide significant association with ICF or PAS. We observed genetic influences on cortical inhibition in older adults with LLD. Replication with larger sample sizes, exploration of clinical phenotype subgroups, and functional analysis of relevant genotypes is warranted to better characterize genetic influences on cortical physiology in LLD. This work is needed to determine whether cortical inhibition may serve as a biomarker to improve diagnostic precision and guide treatment selection in LLD. Subject terms Depression Clinical genetics https://doi.org/10.13039/100000025 U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01 MH083643 R01 MH083660 and P30 MH90333 R01 MH083660 and P30 MH90333 R01 MH083648 Karp Jordan F. Reynolds Charles F. III Lenze Eric J. Blumberger Daniel M. Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health, TorontoU.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)issue-copyright-statement© Springer Nature Limited 2023 ==== Body pmcIntroduction Depression is a multifactorial disease influenced by both genetic and non-genetic factors [1]. In late-life, depression affects approximately 15% of older adults living in the community [2]. Aging and depression are both associated with changes in cortical physiology, such as cortical inhibition, excitation, and plasticity [3]. Exploring the relationship between genetic factors and cortical physiological processes could improve our understanding of biological mechanisms underlying late-life depression (LLD), leading to improved diagnosis and selection of treatment (i.e., biomarker-informed precision psychiatry). Twin studies suggest that 16–55% of the variance in depressive symptoms in older adults may be due to genetic influences, and heritability may be greater with increased age [4, 5]. However, there has been limited success in identifying causal genetic loci for LLD [6]. In a meta-analysis, polymorphisms in apolipoprotein E (APOE), brain-derived neurotrophic factor (BDNF), and serotonin transporter (SLC6A4) genes were associated with LLD [6]. Genome-wide association studies (GWAS) of LLD have identified gene variants associated with cognitive decline and antidepressant response [7, 8]. However, environmental, epigenetic, and polygenic interactions make gene-depression signals difficult to detect and interpret [9]. Neural plasticity and cortical physiology may be potential pathways by which genes influence LLD. Transcranial magnetic stimulation (TMS) can be used to assess various neurophysiological measures. Short interval intracortical inhibition (SICI) measures the suppression of motor-evoked potential (MEP) amplitude when a suprathreshold TMS pulse is pre-conditioned by 1–6 ms with a subthreshold TMS pulse, which is indicative of GABAA inhibitory activity [10]. The cortical silent period (CSP) measures the duration of electromyography suppression when a suprathreshold TMS pulse is given during a sustained muscle contraction, which is indicative of GABAB inhibitory activity [11]. The resting motor threshold (RMT) is a general measure of neuronal excitability, which is influenced by ion channel conductivity [12]. Intracortical facilitation (ICF) measures relative MEP amplitude when a subthreshold TMS pulse precedes a suprathreshold TMS pulse by 10–15 ms, which is indicative of N-methyl-D-aspartate (NMDA) receptor-related excitatory activity [12]. Paired associative stimulation (PAS) refers to repeated median nerve stimulation preceding TMS stimulation and subsequent measurement of MEPs in a target muscle [13]. An interstimulus interval of approximately 25 ms causes an excitatory effect, and changes in subsequent MEP measurements indicate long-term potentiation (LTP) like cortical plasticity [13]. The interaction among depression, aging, and genetics in the pathophysiology of LLD remain unclear. Depression and advancing age have both been related to changes in cortical physiology. Attenuation in GABAA receptor-mediated cortical inhibition has been demonstrated in patients with LLD, healthy older adults, and younger adults with depression [3]. Decreases in cortical excitability and impaired LTP-like plasticity have been shown in healthy older adults and patients with major depressive disorder (MDD) [14–16]. Existing GWAS and candidate gene studies have assessed genetic correlations of various proxy phenotypes of aging, including longevity, age-associated diseases, and physiological characteristics, such as muscle strength and cognitive function [17]. Several genes have been associated with aging, including APOE, GRP78, and FOXO3A [17]. Aging-related genes may influence measures of cortical physiology, as changes in cortical physiology have been observed in healthy older adults [14–16]. Few existing studies have assessed the association of genetic polymorphisms with cortical physiological processes measured by TMS. The BDNF gene encodes a protein that has been implicated in neuronal survival, neuroplasticity, and synaptogenesis [18]. Substitution of valine to methionine at codon 66 (Val66Met) is the most common and well-researched single nucleotide polymorphism (SNP) of BDNF [18]. Multiple studies suggest that there are no differences in SICI, CSP, ICF, or RMT dependent on the Val66Met SNP in healthy participants, though this has not been explored in LLD [19–22]. A few studies report that an increase in post-PAS MEP amplitudes is diminished in those with the Val66Met SNP [23–25]. Even fewer studies have assessed the impact of other SNPs on TMS indices of cortical physiology, and none that are specific to LLD [26–29]. Thus, we conducted the first exploratory GWAS of TMS cortical physiological processes in LLD. Based on the literature reviewed above, we hypothesized that BDNF polymorphisms would be associated with cortical physiology. Second, based on extensive literature on the relationship between neurotransmitters and depression [1, 30], we hypothesized that variations in genes encoding for serotonin [31, 32], norepinephrine [33], dopamine [34, 35], GABA [36, 37], and glutamate receptors and transporters [36, 37] would be associated with cortical physiology changes in LLD. Methods Participants Participants were recruited from the Toronto site of two multi-center clinical trials (ClinicalTrials.gov Identifiers: NCT00892047 and NCT02263248). Participants completed TMS and genetic assessment prior to receiving any treatment intervention in the trials. Informed consent was obtained from all subjects. As described in details previously [38, 39], the main inclusion criteria were: age ≥ 50 (although most participants were 60 years and older), current diagnosis of MDD as per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and Montgomery-Åsberg Depression Rating Scale (MADRS) [40] score ≥15. Exclusion criteria were a diagnosis of dementia; Mini-Mental State Examination (MMSE) score ≤21; a diagnosis of bipolar disorder or a psychotic disorder; substance misuse; an unstable medical condition; and anticonvulsant use. The sample for this analysis comprised 79 participants whose data (clinical, TMS neurophysiology, and genetic) passed quality control. TMS and electromyography measures All TMS measures were conducted in accordance with international consensus guidelines [41]. TMS was delivered to the left motor cortex through a figure-of-eight coil (70 mm loop diameter) using two Magstim 200 stimulators (Magstim, Whitland, UK) connected by a Bistim module. Participants were asked to remain relaxed with their eyes open. Disposable 9 mm electrodes were attached to the abductor pollicis brevis muscle (active electrode) and the interphalangeal joint of the thumb (reference electrode) to measure surface electromyography (EMG). A ground electrode was positioned on the upper forearm. The figure-of-eight coil was held tangentially to the scalp over the left motor cortex “hot spot” to evoke maximum MEP strength, with the handle pointing 45 degrees from the midline to induce a posterior-to-anterior current flow. This position was marked on the scalp to ensure consistent coil placement. RMT was defined as the lowest TMS intensity that elicited an MEP ≥ 50 μV in at least 5 of 10 consecutive trials. When assessing SICI, ICF, and PAS, a suprathreshold TMS test pulse was defined as the TMS intensity that evoked on average a ~1 mV peak-to-peak MEP amplitude. SICI and ICF were measured using paired-pulse TMS with a subthreshold conditioning stimulus (80% of RMT) followed by a test pulse with an interstimulus interval (ISI) of 2 ms (SICI) or 10 ms (ICF). Participants underwent 12 trials of test pulse alone (to determine the average unconditioned MEP amplitude), 12 trials of test pulse 2 ms after the conditioning pulse, and 12 trials of test pulse 10 ms after the conditioning pulse. SICI and ICF ratios were calculated as the average respective conditioned MEP amplitudes divided by the average unconditioned MEP amplitudes. CSP was measured using a suprathreshold pulse (140% of RMT) delivered while participants maintained a voluntary isometric contraction of the abductor pollicis brevis muscle at approximately 20% of maximum contraction. The resulting silent period duration from MEP onset to return of EMG activity was averaged across 10 trials. PAS was assessed using stimulation of the right median nerve paired with a suprathreshold TMS test pulse at an ISI of 25 ms. One hundred and eighty pairs of stimuli were delivered at 0.1 Hz. Twenty TMS pulses at 0.1 Hz were delivered before PAS and at 0-, 15-, 30-, and 60-minutes post-PAS, and resulting MEP amplitudes were measured. Ratios of average and maximum post-PAS MEP amplitudes to pre-PAS MEP amplitudes were calculated. Participants were asked to count the number of peripheral nerve stimulations on the target hand during PAS, as attention affects PAS-induced plasticity. This count was recorded randomly 8 times during the assessment of PAS and used to determine an inattention score. Genotyping and gene-based analyses Genome-wide genotyping was performed using the Illumina PsychArray Beadchip v1.3 endorsed by the Psychiatric Genomics Consortium for participants from both trials. We applied to samples from both trials the quality control (QC) procedure and imputation pipeline reported previously in the first trial [42]. In the second trial, QC was also performed following the standard protocol by Anderson et al. [43] and two participants were removed due to excessive heterozygosity and genotyping missingness. 3827 variants were removed due to missingness, and 266,057 variants with <1% minor allele frequency (MAF) were excluded. 301,495 variants and 34 participants in the second trial entered genome-wide imputation. According to the genipe pipeline, prephasing was first conducted using SHAPEIT2 and 1000 Genomes Phase 3 reference panel, followed by imputation using IMPUTE v2.2 in 5-Mb segments per chromosome [44–47]. The final data were imputed with an information threshold of ≥0.7, a completion rate of ≥0.95, and an imputation probability threshold ≥0.9, resulting in 5,067,675 SNPs after imputation. Out of the final imputed variants, 3,882,161 variants (76.6%) with a MAF ≥ 0.05 were used in the analyses described below. After checking the availability of genetic and TMS data, 45 participants from the first trial and 4,309,635 variants were merged with imputed samples from the second trial. The final merged data file contained 79 participants and 3,331,137 variants. Genome-wide association analysis was conducted on the merged data using PLINK v2.0 [48]. We fitted a linear regression model for each of the phenotypes (SICI at 2 ms, ICF at 10 ms, maximum PAS ratio, average PAS ratio, RMT, and CSP), adjusted for age, MADRS baseline score, and the first three principal components of ancestry inference. Sensitivity analyses were conducted that included sex as an additional covariate. GWAS summary statistics were then utilized to conduct MAGMA gene-based analyses using FUMA with default parameters [49, 50]. Using the 1000 Genome Project Phase 3 (2504 individuals, approximately 84 million SNPs) as the reference panel, 3,331,137 SNPs were assigned to 18,580 genes within a 10 kb window [46]. The genome-wide significance level after correcting for the number of genes was 0.05/18,580 = 2.691 × 10−6. In MAGMA analyses implanted in FUMA, the gene-based Z-score is calculated based on a SNP-wide mean model and we used the Z-score to infer the direction of gene association. To check our hypothesis about the association between the BDNF gene and cortical physiological changes in LLD, we looked for BDNF among the MAGMA results. After MAGMA gene-based analyses, we conducted gene-set enrichment analysis for SICI and CSP, which had significantly associated genes. We used FUMA with default settings and background genes mapped by MAGMA to determine whether there was any overlap between the top 20 associated genes and pre-defined gene sets relevant to a specific phenotype. Results See Table 1 for the sociodemographic and clinical characteristics of the 79 participants included in the GWAS analyses and the subsequent gene-based analyses.Table 1 Sociodemographic, clinical, and neurophysiological characteristics of the participants. Characteristic Median [IQR] or frequency (%) Age 65 [62, 69.9] Sex (Male, %) 29 (36.7%) Ethnicity (European, %) 76 (96.2%) MADRS score 26 [22, 30] SICI 2 ms 0.51 [0.35, 0.76] ICF 10 ms 1.67 [1.30, 2.37] Average PAS ratio 1.14 [0.77, 1.44] Maximum PAS ratio 1.55 [1.02, 2.06] CSP 0.12 [0.10, 0.15] RMT 47 [41, 53.5] CSP cortical silent period, ICF intracortical facilitation, IQR interquartile range, MADRS Montgomery-Åsberg Depression Rating Scale, PAS paired associative stimulation, RMT resting motor threshold, SICI short interval intracortical inhibition. RMT In the 79 participants with RMT data, among the mapped 18,580 genes, none of the 1154 nominally associated genes at the threshold of p < 0.05 reached genome-wide significance (Supplementary Fig. 1). The top association was the MRPS31 gene (Mitochondrial Ribosomal Protein S31, Z = 4.19, p = 1.41 × 10−5; Supplementary Table 1). SICI In the 78 participants with SICI data, MARK4 (Microtubule Affinity Regulating Kinase 4, Z = 4.77, p = 9.35 × 10−7) and PPP1R37 (Protein Phosphatase 1 Regulatory Subunit 37, Z = 4.71, p = 1.22 × 10−6) were positively associated with the SICI ratio with genome-wide significance (Fig. 1, Table 2). Among the independent SNPs assigned to MARK4 and PPP1R37, the top associated SNP was rs75918199 in chromosome 19 (β = 0.50 [0.30, 0.71], p = 8.66 × 10−6). 1122 genes were nominally associated with the phenotype (p < 0.05). Among the top 20 associated genes, the gene-set enrichment analysis showed that the GWAS catalog gene-set of Alzheimer’s disease or pleiotropy had 4 genes (GEMIN7, MARK4, PPP1R37, and NKPD1) overlapped (p = 1.74 × 10−7, adjusted-p = 3.16 × 10−4; Supplementary Table 5).Fig. 1 Gene-based analyses results for SICI. A Gene Manhattan plot. B Gene QQ (quantile-quantile) plot. Note: The dotted red line in (A) is the genome-wide significant threshold p = 2.691 × 10−6. MARK4 Microtubule Affinity Regulating Kinase 4, PPP1R37 Protein Phosphatase 1 Regulatory Subunit 37, GEMIN7 Gem Nuclear Organelle Associated Protein 7, C11orf21 Chromosome 11 Open Reading Frame 21, MARK2 Microtubule Affinity Regulating Kinase 1, RCOR2 REST Corepressor 2, TRA2B Transformer 2 Beta Homolog, NKPD1 NTPase KAP Family P-Loop Domain Containing 1, KRBA1 KRAB-A Domain Containing 1, TARDBP TAR DNA Binding Protein. Table 2 Summary statistics of top 10 genes associated with SICI ratio. Gene Chromosome Start position Stop position NSNPs Z-Statistics p-value MARK4 19 45572546 45818541 225 4.77 9.35 × 10−7 PPP1R37 19 45584654 45661335 157 4.71 1.22 × 10−6 GEMIN7 19 45572453 45604782 91 4.28 9.16 × 10−6 C11orf21 11 2306875 2334279 50 4.25 1.05 × 10−5 MARK2 11 63596400 63688491 62 4.13 1.80 × 10−5 RCOR2 11 63668693 63694316 11 3.91 4.67 × 10−5 TRA2B 3 185623694 185665924 49 3.82 6.70 × 10−5 NKPD1 19 45643008 45673408 9 3.69 1.13 × 10−4 KRBA1 7 149401872 149441664 35 3.68 1.16 × 10−4 TARDBP 1 11062414 11095796 35 3.64 1.37 × 10−4 MARK4 Microtubule Affinity Regulating Kinase 4, PPP1R37 Protein Phosphatase 1 Regulatory Subunit 37, GEMIN7 Gem Nuclear Organelle Associated Protein 7, C11orf21 Chromosome 11 Open Reading Frame 21, MARK2 Microtubule Affinity Regulating Kinase 1, RCOR2 REST Corepressor 2, TRA2B Transformer 2 Beta Homolog, NKPD1 NTPase KAP Family P-Loop Domain Containing 1, KRBA1 KRAB-A Domain Containing 1, TARDBP TAR DNA Binding Protein. CSP In 76 participants with CSP data, EGFLAM (EGF-like Fibronectin Type III and Laminin G Domains, Z = 4.94, p = 3.82 × 10−7) was positively associated with CSP with genome-wide significance (Fig. 2, Table 3). Among the independent SNPs assigned to EGFLAM, the top associated SNP was rs2561139 in chromosome 5 (β = −0.02 [−0.03, −0.01], p = 7.85 × 10−6). 1126 genes were nominally associated with the phenotype (p < 0.05). None of the top 20 associated genes were overrepresented in the pre-defined GWAS catalog reported gene sets.Fig. 2 Gene-based analyses results for CSP. A Gene Manhattan plot. B Gene QQ (quantile-quantile) plot. Note: The dotted red line in (A) is the genome-wide significant threshold p = 2.691 × 10−6. EGFLAM EGF Like - Fibronectin Type III and Laminin G Domains, FHL2 Four And A Half LIM Domains 2, SPTB Spectrin Beta Erythrocytic, PCK1 Phosphoenolpyruvate Carboxykinase 1, NOTCH4 Notch Receptor 4, AOX1 Aldehyde Oxidase 1, C17orf103 N-Acetyltransferase Domain Containing 1, GNG11 G Protein Subunit Gamma 11, TNFAIP6 TNF Alpha Induced Protein 6, FRYL FRY Like Transcription Coactivator. Table 3 Summary statistics of top 10 genes associated with CSP. Gene Chromosome Start position Stop position NSNPs Z-Statistics p-value EGFLAM 5 38248511 38475123 205 4.94 3.82 × 10−7 FHL2 2 105964169 106064970 106 3.89 5.01 × 10−5 SPTB 14 65203002 65356601 225 3.75 8.91 × 10−5 PCK1 20 56126136 56151513 29 3.74 9.20 × 10−5 NOTCH4 6 32152620 32201844 166 3.71 1.03 × 10−4 AOX1 2 201440591 201551787 150 3.64 1.34 × 10−4 C17orf103 17 21132183 21166722 16 3.55 1.95 × 10−4 GNG11 7 93541011 93567922 27 3.53 2.12 × 10−4 TNFAIP6 2 152204106 152246560 51 3.43 3.06 × 10−4 FRYL 4 48489378 48792339 164 3.42 3.11 × 10−4 EGFLAM EGF-Like Fibronectin Type III and Laminin G Domains, FHL2 Four And A Half LIM Domains 2, SPTB Spectrin Beta Erythrocytic, PCK1 Phosphoenolpyruvate Carboxykinase 1, NOTCH4 Notch Receptor 4, AOX1 Aldehyde Oxidase 1, C17orf103 N-Acetyltransferase Domain Containing 1, GNG11 G Protein Subunit Gamma 11, TNFAIP6 TNF Alpha Induced Protein 6, FRYL FRY Like Transcription Coactivator. ICF In the 77 participants with ICF data, none of the 11,161 nominally associated genes reached genome-wide significance (Supplementary Fig. 2). The top association was SMIM17 gene (Small Integral Membrane Protein 17, Z = 4.30, p = 8.65 × 10−6; Supplementary Table 2). Average PAS ratio In the 63 participants with a PAS ratio, none of the 1067 nominally associated genes reached genome-wide significance (Supplementary Fig. 3). The top association was the TRIM58 gene (Tripartite Motif Containing 58, Z = 3.72, p = 9.95 × 10−5; Supplementary Table 3). Maximum PAS ratio In the 63 participants with a PAS ratio, none of the 1107 nominally associated genes reached genome-wide significance (Supplementary Fig. 4). The top association was the PRKAG3 gene (Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 3, Z = 3.99, p = 3.37 × 10−5; Supplementary Table 4). Sensitivity Analyses With sex as an additional covariate, PPP1R37 was not significantly associated with SICI (Z = 4.53, p = 2.90 × 10−6). MARK4 remained associated with SICI (Z = 4.58, p = 2.38 × 10−6) and EGFLAM remained associated with CSP (Z = 4.94, p = 3.99 × 10−7) with genome-wide significance. There were no other significant associations. Discussion We used exploratory GWAS and gene-based analyses to assess the association between genes and TMS measures of cortical inhibition, facilitation, or LTP-like plasticity in LLD. We had three key findings. First, MARK4 (which encodes microtubule affinity-regulating kinase 4) and PPP1R37 (which encodes protein phosphatase 1 regulatory subunit 37) showed genome-wide significant associations with SICI, an indirect measure of GABAA receptor-mediated cortical inhibition. Second, EGFLAM (which encodes EGF-like fibronectin type III and laminin G domains) showed genome-wide significant association with CSP, an indirect measure of GABAB receptor-mediated cortical inhibition. Third, no genes showed a genome-wide significant association with RMT, ICF, or PAS. These findings suggest there may be genetic influences on cortical inhibition in older adults with LLD. Further research is indicated to determine whether cortical inhibition may serve as a biomarker to improve diagnostic precision and treatment selection in this patient population. SICI is believed to be an indirect measure of GABAA inhibitory activity [10]. MARK4 and PPP1R37 were both associated with decreased SICI in our sample. MARK4 encodes a protein that may be involved in regulation of microtubule networks in neurons [51]. Increased expression of MARK4 has been shown in Alzheimer’s disease (AD), and in vitro studies suggest MARK4 can potentiate tau aggregation [51]. Based on gene enrichment testing in FUMA, both MARK4 and PPP1R37 have been reported in “Alzheimer’s disease or HDL levels” in the GWAS catalog (see Supplementary Fig. 6). A de novo mutation of MARK4 has been associated with the production of abnormally phosphorylated tau [51]. In vivo studies in mice suggest tau expression may be associated with synaptic plasticity deficits [52]. Elevated tau has also been associated with depression, and recent literature suggests that LLD has a different distribution of tau compared to AD [53, 54]. In theory, tau aggregation could inhibit activity of GABAergic neurons, like its effects on hippocampal neurons in AD [55]. Furthermore, MARK4 has also been shown to be upregulated in ischemic axonal injury [56]. Cerebrovascular disease (CVD) may also contribute to LLD, and CVD has also been linked to AD [57, 58]. PPP1R37 encodes for a protein believed to inhibit phosphatase activity of protein phosphatase 1 (PP1) complexes [59]. Limited literature exists on the function of this protein. A transcriptome-wide analysis found an association of differential expression of PPP1R37 in hippocampal tissue with AD compared to controls [60]. Post-mortem studies of patients with AD suggest that PP1 is involved in regulation of tau dephosphorylation [61]. Experiments in mice suggest PP1 activity mediates effects of β-amyloid on synaptic plasticity in AD and PP1 has a role in long-term depression of neuronal activity [61]. Thus, variance in expression of PPP1R37 could lead to aberrant phosphorylation of neurotoxic aggregates, with subsequent effects on GABAergic function. Of note, PPP1R37 was not significantly associated with SICI in sensitivity analyses including sex as an additional covariate. Sex was not included as a covariate in the primary analyses due to limited sample size, however, there is one existing study that suggests biological males may have reduced SICI compared to females [62]. More studies are needed to characterize the role of sex in relation to depression and cortical physiology changes. Existing literature reports a significant association between LLD and AD, with LLD being a risk factor or prodrome for AD [63]. Several biological mechanisms may overlap between depression and AD, including: inflammatory changes, CVD, decreased neurotrophic factors, and deposits of β-amyloid plaques [63]. The potential associations of both MARK4 and PPP1R37 with AD-related processes is supportive of a link between LLD and AD. The age-by-disease interaction hypothesis of LLD suggests age-related changes in gene expression in the brain may increase susceptibility to multiple neurodegenerative disorders simultaneously [64]. A previous study showed that deficits in cortical inhibition measured with SICI can occur with aging, independent of depression status [3]. Given that the present study is a cross-sectional analysis of cortical physiology in LLD and there is no age-matched control group, we cannot assess whether the potential effects of MARK4 and PPP1R37 are related to depression, aging, or both. CSP is believed to be an indirect measure of GABAB inhibitory activity [11]. EGFLAM was associated with increased CSP in our sample. EGFLAM encodes a protein believed to enable calcium ion and glycosaminoglycan binding activity [65]. Previous GWAS studies suggest EGFLAM is associated with mathematical ability, educational attainment, and SSRI response [66–68]. There are no prior studies that have investigated the effect of EGFLAM on TMS cortical physiology measures. More studies are needed to clarify if EGFLAM is associated with cortical physiology. Identifying predictors of response is important to optimize treatment selection for LLD. In a previous study, a combination of TMS measures of cortical excitability, with clinical and demographic data predicted response to venlafaxine treatment in LLD with 73% accuracy [69]. The combination of TMS measures with additional biomarkers, such as genetic data, may be useful for the development of models with higher accuracy. As cortical physiological processes are influenced by both neurostimulation and pharmacotherapy, further investigation to characterize the genetic determinants of cortical physiology in LLD may help identify genetic biomarkers of treatment response. In our study, BDNF did not show a genome-wide significant association with SICI, CSP, ICF, RMT, or PAS. The association of BDNF genotype with TMS cortical physiology measures has been previously investigated. In a few studies in healthy participants, there were no differences in SICI, ICF, CSP, or RMT based on BDNF genotype [19–22]. In three small studies in young healthy participants (N = 18–32), there was an increase in post-PAS MEP amplitudes in those with the BDNF valine/valine genotype, but not in those with the Val66Met SNP [23–25]. One case-control study found a significant interaction between BDNF genotype and catechol-O-methyltransferase genotype in PAS response, suggesting there are likely polygenic determinants of LTP-like plasticity [70]. A case-control study of 23 participants with MDD matched to 23 healthy controls reported greater post-PAS MEP amplitudes in healthy controls than participants with depression, though there was no statistically significant effect of BDNF genotype on response to PAS [71]. There are also contradictory reports on the effect of the Val66Met SNP on TMS cortical physiology measures in response to interventions such as motor training, intermittent theta-burst stimulation, and transcranial direct current stimulation [19–22]. In light of our findings, based on lack of agreement in studies, more studies are needed to clarify whether BDNF is associated with cortical physiology in younger and older adults with and without depression. A limited number of prior studies have assessed the association of other genes with TMS cortical physiology measures. A randomized crossover trial of 92 healthy participants found no effect of the SCN1A rs3812717 polymorphism on SICI, ICF, CSP, or RMT, however, the SCNIA genotype modulated the effect of carbamazepine on CSP [26]. A cross-sectional analysis of 77 healthy participants found two common TRPV1 SNPs do not have an effect on SICI, ICF, CSP, or RMT [27]. A small randomized crossover trial in children with Attention-deficit/hyperactivity disorder (ADHD) found that genetic variation in the dopamine transporter (DAT1) was not associated with baseline differences in SICI or ICF, but DAT1 genotype influenced the effect of stimulant administration on these measures [72]. A small exploratory study of eight healthy participants suggested allelic variation in the serotonin transporter promoter (5-HTTLPR) is associated with differential cortical excitability at baseline or in response to citalopram administration [28]. In addition, a case-control study in 24 participants with mild cognitive impairment compared to 24 age-matched controls found that APOE genotype was not correlated with response to PAS [29]. There are no prior studies that have investigated the effect of genes on TMS cortical physiology measures in LLD specifically. In our study, SCN1A, TRPV1, DAT1, and APOE did not show an association with TMS cortical physiology measures, and more studies are needed to clarify whether these genes are associated with cortical physiology processes. Some strengths of our analysis include comprehensive clinical characterization of the patient sample and integration of several biological measures related to genome-wide genotyping and TMS neurophysiology. LLD is a heterogenous disorder in relation to pathophysiology, clinical phenotype, and intervention response. Recent literature suggests the importance of transdisciplinary approaches to research in psychiatry, as biological systems rarely act in isolation [73]. Comprehensive clinical and biological characterization of patients receiving treatment for LLD is needed given the complexity of depression and aging. There were also several limitations in our analysis. First and foremost, our sample size was small, increasing the risk of type II error and potentially preventing us from finding true associations. Second, our results were specific to the motor cortex, and it is unclear how they would relate to other cortical regions. Future studies should assess genetic correlations of TMS measures in the dorsolateral prefrontal cortex directly, using TMS-EEG [74]. We were unable to assess for epistasis, that has been shown to have salient impacts on depression phenotypes [75, 76]. We were also unable to assess for causal associations of genes with the TMS processes, as this would require functional characterization of genotypes. As there is no control group in the analysis, we are unable to distinguish whether the identified SNPs are more relevant to depression or aging. Furthermore, additional covariates that may impact cortical physiology, such as prescribed medications and comorbidities, were not accounted for in this analysis. Limited evidence suggests that single doses of specific serotonin reuptake inhibitors and norepinephrine reuptake inhibitors may have transient effects on cortical physiology [31–33]. Several studies suggest that administration of dopamine agonists and antagonists can modulate cortical inhibition, facilitation, and plasticity [34, 35, 77]. The impacts of other psychotropic classes, treatment duration, and medication interactions on cortical physiology have not been well-characterized. In addition, medical comorbidities are relatively common in older adults. Prior studies show that following stroke there may be reduced SICI, which may persist throughout the recovery course [78, 79]. The impact of other comorbidities, such as cerebrovascular disease or other neurological conditions, on cortical physiology is not well-defined. More studies are needed to elucidate the role of medications and comorbidities in cortical physiology. In conclusion, our results suggest there may be genetic influences on cortical physiology in LLD. MARK4 and PPP1R37 (two genes that have been linked to AD), and EGFLAM, may influence cortical inhibition in LLD. Replication with larger sample sizes and functional analyses of relevant SNPs is needed to determine possible causal associations of genes with TMS measures. With an increasing number of treatment options available for LLD, it is important to characterize the influences of genetics on cortical neurophysiology. This could facilitate optimization of treatment selection and advancement of personalized medicine for LLD. Supplementary information Supplementary Information Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure 3 Supplementary Figure 4 Supplementary Figure 5 Supplementary Figure 6 Supplementary information The online version contains supplementary material available at 10.1038/s41398-023-02532-0. Acknowledgements We acknowledge the CAMH Biobank and Molecular Core Family for preparing and genotyping the data. Analyses were performed on the CAMH Specialized Computing Cluster (SCC). The SCC is funded by The Canada Foundation for Innovation, Research Hospital Fund. This work was also funded by the National Institute of Mental Health (R01 MH083660, P30 MH90333, R01 MH083648, R01 MH083643, R34 MH101371, R01 DA025931), the UPMC Endowment in Geriatric Psychiatry, the Taylor Family Institute for Innovative Psychiatric Research, the Washington University Institute of Clinical and Translational Sciences grant (UL1 TR000448), and the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health, Toronto. Author contributions RAW, XM, DJM, and DMB conceived and designed the study. All authors contributed to acquisition, analysis, or interpretation of data. RAW, XM, DJM, and DMB were involved in drafting the manuscript. All authors contributed to critical revisions of the manuscript. XM completed statistical analysis. DJM and DMB provided supervision. Competing interests None for RAW, XM, SSME, VSM, JIL, and DJM. TKR has received research support from Brain Canada, Brain and Behavior Research Foundation, BrightFocus Foundation, Canada Foundation for Innovation, Canada Research Chair, Canadian Institutes of Health Research, Centre for Aging and Brain Health Innovation, National Institutes of Health, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, and the Weston Brain Institute. Dr. Rajji also received for an investigator-initiated study in-kind equipment support from Newronika, and in-kind research online accounts from Scientific Brain Training Pro, and participated in 2021 and 2022 in an advisory activity for Biogen Canada Inc. Dr. Rajji is also an inventor on the United States Provisional Patent No. 17/396,030 that describes cell-based assays and kits for assessing serum cholinergic receptor activity. BHM is supported in part by the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received during the past five years research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). Within the past five years, he has been an unpaid consultant to Myriad Neuroscience. JFK receipt of medication supplies for investigator-initiated studies from Pfizer and Indivior. Service on scientific advisory board of Aifred Health with potential for equity. He has served as a scientific advisor for Biogen. CFR has received research support from the NIH, PCORI, the Center for Medicare and Medicaid Services, the American Foundation for Suicide Prevention, the Brain and Behavior Research Foundation, and the Commonwealth of Pennsylvania. Bristol Meyers Squib and Pfizer have provided pharmaceutical supplies for his NIH sponsored research. EJL receives research support from the US National Institute of Health (NIH), the Patient-Centered Outcomes Research Institute (PCORI), McKnight Brain Research Foundation, Takeda, Lundbeck, and consulting fees (past) from Janssen and Jazz Pharmaceuticals. ZJD has received research and equipment in-kind support for an investigator-initiated study through Brainsway Inc and Magventure Inc and industry-initiated trials through Magnus Inc. He also currently serves on the scientific advisory board for Brainsway Inc. His work has been supported by the National Institutes of Mental Health (NIMH), the Canadian Institutes of Health Research (CIHR), Brain Canada and the Temerty Family, Grant and Kreutzcamp Family Foundations. DMB receives research support from the Canadian Institutes of Health Research (CIHR), National Institutes of Health – US (NIH), Weston Brain Institute, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. and he is the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He receives in-kind equipment support from Magventure for two investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. He has participated in an advisory board for Janssen. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Rafae A. Wathra, Xiaoyu Men. These authors jointly supervised this work: Daniel J. Müller, Daniel M. Blumberger. ==== Refs References 1. Shao X, Zhu G. Associations among monoamine neurotransmitter pathways, personality traits, and major depressive disorder. Front Psychiatry. 2020;11:381. 2. Blazer DG Depression in late life: review and commentary J Gerontol A Biol Sci Med Sci 2003 58 M249 65 10.1093/gerona/58.3.M249 3. Lissemore JI Bhandari A Mulsant BH Lenze EJ Reynolds CF Karp JF Reduced GABAergic cortical inhibition in aging and depression Neuropsychopharmacology 2018 43 2277 84 10.1038/s41386-018-0093-x 29849055 4. Gatz M Pederson NL Plomin R Nesselroade JR Importance of shared genes and shared environments for symptoms of depression in older adults J Abnorm Psychol 1992 101 701 8 10.1037/0021-843X.101.4.701 1430610 5. Carmelli D Swan GE Kelly-Hayes M Wolf PA Reed T Miller B Longitudinal changes in the contribution of genetic and environmental influences to symptoms of depression in older male twins Psychol Aging 2000 15 505 10 10.1037/0882-7974.15.3.505 11014713 6. Tsang RSM Mather KA Sachdev PS Reppermund S Systematic review and meta-analysis of genetic studies of late-life depression Neurosci Biobehav Rev 2017 75 129 39 10.1016/j.neubiorev.2017.01.028 28137459 7. Eyre HA Eskin A Nelson SF St Cyr NM Siddarth P Baune BT Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study Int J Geriatr Psychiatry 2016 31 510 7 10.1002/gps.4356 26471432 8. Steffens DC, Garrett ME, Soldano KL, McQuoid DR, Ashley-Koch AE, Potter GG. Genome-wide screen to identify genetic loci associated with cognitive decline in late-life depression. Int Psychogeriatr. 2020;1–9. 9. Mullins N Lewis CM Genetics of depression: progress at last Curr Psychiatry Rep 2017 19 43 10.1007/s11920-017-0803-9 28608123 10. Kujirai T Caramia MD Rothwell JC Day BL Thompson PD Ferbert A Corticocortical inhibition in human motor cortex J Physiol 1993 471 501 19 10.1113/jphysiol.1993.sp019912 8120818 11. Cantello R Gianelli M Civardi C Mutani R Magnetic brain stimulation: the silent period after the motor evoked potential Neurology 1992 42 1951 9 10.1212/WNL.42.10.1951 1407578 12. Paulus W State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation Brain Stimul 2008 1 151 63 10.1016/j.brs.2008.06.002 20633382 13. Wolters A Sandbrink F Schlottmann A Kunesch E Stefan K Cohen LG A temporally asymmetric Hebbian rule governing plasticity in the human motor cortex J Neurophysiol 2003 89 2339 45 10.1152/jn.00900.2002 12612033 14. Cantone M, Bramanti A, Lanza G, Pennisi M, Bramanti P, Pennisi G, et al. Cortical plasticity in depression. ASN Neuro. 2017;9:1–15. 15. Cueva AS Galhardoni R Cury RG Parravano DC Correa G Araujo H Normative data of cortical excitability measurements obtained by transcranial magnetic stimulation in healthy subjects Neurophysiol Clin 2016 46 43 51 10.1016/j.neucli.2015.12.003 26924308 16. Tecchio F Zappasodi F Pasqualetti P Gennaro LD Pellicciari MC Ercolani M Age dependence of primary motor cortex plasticity induced by paired associative stimulation Clin Neurophysiol 2008 119 675 82 10.1016/j.clinph.2007.10.023 18178522 17. Melzer D Pilling LC Ferrucci L The genetics of human ageing Nat Rev Genet 2020 21 88 101 10.1038/s41576-019-0183-6 31690828 18. Levy MJF Boulle F Steinbusch HW van den Hove DLA Kenis G Lanfumey L Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression Psychopharmacology 2018 235 2195 220 10.1007/s00213-018-4950-4 29961124 19. Morin-Moncet O Latulipe-Loiselle A Therrien-Blanchet JM Theoret H BDNF Val66Met polymorphism is associated with altered activity-dependent modulation of short-interval intracortical inhibition in bilateral M1 PLoS ONE 2018 13 e0197505 10.1371/journal.pone.0197505 29856758 20. Lee M Kim SE Kim WS Lee J Yoo HK Park KD Interaction of motor training and intermittent theta burst stimulation in modulating motor cortical plasticity: influence of BDNF Val66Met polymorphism Chen R, editor PLoS ONE 2013 8 e57690 10.1371/journal.pone.0057690 21. Di Lazzaro V Manganelli F Dileone M Notturno F Esposito M Capasso M The effects of prolonged cathodal direct current stimulation on the excitatory and inhibitory circuits of the ipsilateral and contralateral motor cortex J Neural Transm 2012 119 1499 506 10.1007/s00702-012-0845-4 22711234 22. Frazer A Williams J Spittles M Rantalainen T Kidgell D Anodal transcranial direct current stimulation of the motor cortex increases cortical voluntary activation and neural plasticity Muscle Nerve 2016 54 903 13 10.1002/mus.25143 27065472 23. Cirillo J Hughes J Ridding M Thomas PQ Semmler JG Differential modulation of motor cortex excitability in BDNF Met allele carriers following experimentally induced and use-dependent plasticity Eur J Neurosci 2012 36 2640 9 10.1111/j.1460-9568.2012.08177.x 22694150 24. Cheeran B Talelli P Mori F Koch G Suppa A Edwards M A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS J Physiol 2008 586 5717 25 10.1113/jphysiol.2008.159905 18845611 25. Missitzi J Gentner R Geladas N Politis P Karandreas N Classen J Plasticity in human motor cortex is in part genetically determined J Physiol 2011 589 297 306 10.1113/jphysiol.2010.200600 21098007 26. Menzler K Hermsen A Balkenhol K Duddek C Bugiel H Bauer S A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability-a pharmacogenetic transcranial magnetic stimulation study Epilepsia 2014 55 362 9 10.1111/epi.12515 24417206 27. Mori F Ribolsi M Kusayanagi H Monteleone F Mantovani V Buttari F TRPV1 channels regulate cortical excitability in humans J Neurosci 2012 32 873 9 10.1523/JNEUROSCI.2531-11.2012 22262885 28. Eichhammer P Langguth B Wiegand R Kharraz A Frick U Hajak G Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI) Psychopharmacology 2003 166 294 7 10.1007/s00213-002-1370-1 12563545 29. Lahr J Peter J Minkova L Lauer E Reis J Heimbach B No difference in paired associative stimulation induced cortical neuroplasticity between patients with mild cognitive impairment and elderly controls Clin Neurophysiol 2016 127 1254 60 10.1016/j.clinph.2015.08.010 26394910 30. Duman RS Sanacora G Krystal JH Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments Neuron 2019 102 75 90 10.1016/j.neuron.2019.03.013 30946828 31. Robol E Fiaschi A Manganotti P Effects of citalopram on the excitability of the human motor cortex: a paired magnetic stimulation study J Neurol Sci 2004 221 41 6 10.1016/j.jns.2004.03.007 15178212 32. Batsikadze G Paulus W Kuo MF Nitsche MA Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex Neuropsychopharmacology 2013 38 2260 7 10.1038/npp.2013.127 23680943 33. Herwig U Bräuer K Connemann B Spitzer M Schönfeldt-Lecuona C Intracortical excitability is modulated by a norepinephrine-reuptake inhibitor as measured with paired-pulse transcranial magnetic stimulation Psychopharmacology 2002 164 228 32 10.1007/s00213-002-1206-z 12404087 34. Fresnoza S Stiksrud E Klinker F Liebetanz D Paulus W Kuo MF Dosage-dependent effect of dopamine D2 receptor activation on motor cortex plasticity in humans J Neurosci 2014 34 10701 9 10.1523/JNEUROSCI.0832-14.2014 25100602 35. Thirugnanasambandam N Grundey J Paulus W Nitsche MA Dose-dependent nonlinear effect of l-DOPA on paired associative stimulation-induced neuroplasticity in humans J Neurosci 2011 31 5294 9 10.1523/JNEUROSCI.6258-10.2011 21471364 36. Ziemann U Pharmacology of TMS Suppl Clin Neurophysiol 2003 56 226 31 10.1016/S1567-424X(09)70226-0 14677399 37. Cohen Kadosh K Krause B King AJ Near J Cohen Kadosh R Linking GABA and glutamate levels to cognitive skill acquisition during development Hum Brain Mapp 2015 36 4334 45 10.1002/hbm.22921 26350618 38. Lenze EJ Mulsant BH Blumberger DM Karp JF Newcomer JW Anderson SJ Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial Lancet 2015 386 2404 12 10.1016/S0140-6736(15)00308-6 26423182 39. Lin C Karim HT Pecina M Aizenstein HJ Lenze EJ Blumberger DM Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression Neuroimage Clin 2019 21 101679 10.1016/j.nicl.2019.101679 30685701 40. Montgomery SA Asberg M A new depression scale designed to be sensitive to change Br J Psychiatry 1979 134 382 9 10.1192/bjp.134.4.382 444788 41. Chipchase L Schabrun S Cohen L Hodges P Ridding M Rothwell J A checklist for assessing the methodological quality of studies using transcranial magnetic stimulation to study the motor system: an international consensus study Clin Neurophysiol 2012 123 1698 704 10.1016/j.clinph.2012.05.003 22647458 42. Marshe VS Maciukiewicz M Hauschild AC Islam F Qin L Tiwari AK Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response Transl Psychiatry 2021 11 127 10.1038/s41398-021-01248-3 33589590 43. Anderson CA Pettersson FH Clarke GM Cardon LR Morris AP Zondervan KT Data quality control in genetic case-control association studies Nat Protoc 2010 5 1564 73 10.1038/nprot.2010.116 21085122 44. Lemieux Perreault LP Legault MA Asselin G Dubé MP genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools Bioinformatics 2016 32 3661 3 10.1093/bioinformatics/btw487 27497439 45. van Leeuwen EM Kanterakis A Deelen P Kattenberg MV Genome of the Netherlands ConsortiumSlagboom PE Population-specific genotype imputations using minimac or IMPUTE2 Nat Protoc 2015 10 1285 96 10.1038/nprot.2015.077 26226460 46. Auton A Abecasis GR Altshuler DM Durbin RM Abecasis GR Bentley DR A global reference for human genetic variation Nature 2015 526 68 74 10.1038/nature15393 26432245 47. Loh PR Danecek P Palamara PF Fuchsberger C Reshef AY Finucane KH Reference-based phasing using the Haplotype Reference Consortium panel Nat Genet 2016 48 1443 8 10.1038/ng.3679 27694958 48. Purcell S Neale B Todd-Brown K Thomas L Ferreira MAR Bender D PLINK: a tool set for whole-genome association and population-based linkage analyses Am J Hum Genet 2007 81 559 75 10.1086/519795 17701901 49. Leeuw CA de, Mooij JM Heskes T Posthuma D MAGMA: generalized gene-set analysis of GWAS data PLOS Comput Biol 2015 11 e1004219 10.1371/journal.pcbi.1004219 25885710 50. Watanabe K Taskesen E van Bochoven A Posthuma D Functional mapping and annotation of genetic associations with FUMA Nat Commun 2017 8 1826 10.1038/s41467-017-01261-5 29184056 51. Oba T Saito T Asada A Shimizu S Iijima KM Ando K Microtubule affinity–regulating kinase 4 with an Alzheimer’s disease-related mutation promotes tau accumulation and exacerbates neurodegeneration J Biol Chem 2020 295 17138 47 10.1074/jbc.RA120.014420 33020179 52. Biundo F Del Prete D Zhang H Arancio O D’Adamio L A role for tau in learning, memory and synaptic plasticity Sci Rep 2018 8 3184 10.1038/s41598-018-21596-3 29453339 53. Babulal GM Roe CM Stout SH Rajasekar G Wisch JK Benzinger TLS Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults J Alzheimers Dis 2020 74 1045 55 10.3233/JAD-191078 32144985 54. Loureiro JC Stella F Pais MV Radanovic M Canineu PR Joaquim HPG Cognitive impairment in remitted late-life depression is not associated with Alzheimer’s disease-related CSF biomarkers J Affect Disord 2020 272 409 16 10.1016/j.jad.2020.03.166 32553384 55. Jouanne M Rault S Voisin-Chiret AS Tau protein aggregation in Alzheimer’s disease: an attractive target for the development of novel therapeutic agents Eur J Med Chem 2017 139 153 67 10.1016/j.ejmech.2017.07.070 28800454 56. Hayden EY Putman J Nunez S Shin WS Oberoi M Charreton M Ischemic axonal injury up-regulates MARK4 in cortical neurons and primes tau phosphorylation and aggregation Acta Neuropathol Commun 2019 7 135 10.1186/s40478-019-0783-6 31429800 57. Alexopoulos GS Mechanisms and treatment of late-life depression. Transl Psychiatry. 2019;9:188. 58. Attems J Jellinger KA The overlap between vascular disease and Alzheimer’s disease - lessons from pathology BMC Med 2014 12 206 10.1186/s12916-014-0206-2 25385447 59. PPP1R37 protein phosphatase 1 regulatory subunit 37 [Homo sapiens (human)] - Gene - NCBI. [cited 2022 Feb 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/284352. 60. Liu N Xu J Liu H Zhang S Li M Zhou Y Hippocampal transcriptome-wide association study and neurobiological pathway analysis for Alzheimer’s disease PLoS Genet 2021 17 e1009363 10.1371/journal.pgen.1009363 33630843 61. Braithwaite SP Stock JB Lombroso PJ Nairn AC Protein phosphatases and Alzheimer’s disease Prog Mol Biol Transl Sci 2012 106 343 79 10.1016/B978-0-12-396456-4.00012-2 22340724 62. Shibuya K Park SB Geevasinga N Huynh W Simon NG Menon P Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function Clin Neurophysiol 2016 127 2355 61 10.1016/j.clinph.2016.03.009 27178853 63. Byers AL Yaffe K Depression and risk of developing dementia Nat Rev Neurol 2011 7 323 31 10.1038/nrneurol.2011.60 21537355 64. McKinney BC, Sibille E. The age-by-disease interaction hypothesis of late-life depression. Am J Geriatr Psychiatry. 2013;21. 10.1016/j.jagp.2013.01.053. 65. EGFLAM EGF like, fibronectin type III and laminin G domains [Homo sapiens (human)] - Gene - NCBI [Internet]. [cited 2022 Nov 18]. Available from: https://www.ncbi.nlm.nih.gov/gene/133584#summary. 66. Adkins DE Clark SL Åberg K Hettema JM Bukszár J McClay JL Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D Transl Psychiatry 2012 2 e129 10.1038/tp.2012.57 22760553 67. Lee JJ Wedow R Okbay A Kong E Maghzian O Zacher M Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals Nat Genet 2018 50 1112 21 10.1038/s41588-018-0147-3 30038396 68. Okbay A Wu Y Wang N Jayashankar H Bennett M Nehzati SM Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals Nat Genet 2022 54 437 49 10.1038/s41588-022-01016-z 35361970 69. Lissemore JI Mulsant BH Bonner AJ Butters MA Chen R Downar J Transcranial magnetic stimulation indices of cortical excitability enhance the prediction of response to pharmacotherapy in late-life depression Biol Psychiatry: Cogn Neurosci Neuroimaging 2022 7 265 75 34311121 70. Witte AV Kürten J Jansen S Schirmacher A Brand E Sommer J Interaction of BDNF and COMT polymorphisms on paired-associative stimulation-induced cortical plasticity J Neurosci 2012 32 4553 61 10.1523/JNEUROSCI.6010-11.2012 22457502 71. Player MJ Taylor JL Weickert CS Alonzo A Sachdev P Martin D Neuroplasticity in depressed individuals compared with healthy controls Neuropsychopharmacology 2013 38 2101 8 10.1038/npp.2013.126 23676792 72. Gilbert DL Wang Z Sallee FR Ridel KR Merhar S Zhang J Dopamine transporter genotype influences the physiological response to medication in ADHD Brain 2006 129 2038 46 10.1093/brain/awl147 16760197 73. Reynolds CF III Weissman MM Transdisciplinary science and research training in psychiatry: a robust approach to innovation JAMA Psychiatry 2022 79 839 40 10.1001/jamapsychiatry.2022.1788 35830189 74. Tremblay S Rogasch NC Premoli I Blumberger DM Casarotto S Chen R Clinical utility and prospective of TMS-EEG Clin Neurophysiol 2019 130 802 44 10.1016/j.clinph.2019.01.001 30772238 75. Tam V Patel N Turcotte M Bossé Y Paré G Meyre D Benefits and limitations of genome-wide association studies Nat Rev Genet 2019 20 467 84 10.1038/s41576-019-0127-1 31068683 76. Penner-Goeke S Binder EB Epigenetics and depression Dialogues Clin Neurosci 2019 21 397 405 10.31887/DCNS.2019.21.4/ebinder 31949407 77. Nitsche MA Kuo MF Grosch J Bergner C Monte-Silva K Paulus W D1-receptor impact on neuroplasticity in humans J Neurosci 2009 29 2648 53 10.1523/JNEUROSCI.5366-08.2009 19244540 78. Hummel FC Steven B Hoppe J Heise K Thomalla G Cohen LG Deficient intracortical inhibition (SICI) during movement preparation after chronic stroke Neurology 2009 72 1766 72 10.1212/WNL.0b013e3181a609c5 19451532 79. Ding Q Triggs WJ Kamath SM Patten C Short intracortical inhibition during voluntary movement reveals persistent impairment post-stroke Front Neurol 2019 9 1105 10.3389/fneur.2018.01105 30662425